



## PROCESSING OF BONE MARROW MONONUCLEAR STEM CELLS IN ACUTE SPINAL CORD INJURY

**<sup>1</sup>\*Tulika Chandra MD., <sup>2</sup>Dr. R.N.Srivastava MS., <sup>3</sup>Dr. Saroj Chooramani Gopal Mch., S.Nishat Fatima Rizvi<sup>1</sup>  
PhD Scholar., Devisha Agarwal<sup>1</sup>MBBS Scholar.**

<sup>1</sup>Department of Transfusion Medicine and Blood Bank, King Georg's Medical University, Lucknow, Uttar Pradesh, India.

<sup>2</sup>Department of Orthopaedic surgery, King Georg's Medical University, Lucknow, Uttar Pradesh, India.

<sup>3</sup>Department of Paediatric Surgery, BHU, Varanasi, Uttar Pradesh, India.

**\*Correspondence for Author: Dr. Tulika Chandra**

Department of Transfusion Medicine and Blood Bank, King Georg's Medical University, Lucknow, Uttar Pradesh, India.

Article Received on 21/10/2015

Article Revised on 12/11/2015

Article Accepted on 03/12/2015

### ABSTRACT

The present study was conducted to evaluate the concentration of MNCs and its CD 34 positive cell fraction in the infusion sample of the autologous bone marrow concentrate used in the SCI patients. Bone marrow was the first source of mononuclear stem cells for experimental and later for clinical use. For experimental use, it is still probably the best and most accessible. 44 patients with loss of motor and sensory functions due to injury between T6 and L3 skeletal levels were selected. Finding shows that middle age groups [Mean  $\pm$  SD (Range) = 32.70  $\pm$  9.80] are more prone to the SCI. among all the mode of injuries, the direct fall from height is the most common one (57 %) and L1, L2 and T12 are three main levels of motor loss due to SCI. There was a significant positive correlation of the total volume of bone marrow aspirated with bone marrow derived mononuclear cells ( $p < 0.01$ ,  $r = 0.92$ ). The volume of bone marrow aspirated had a significant positive correlation with the number of bone marrow derived CD34+ cells ( $p < 0.01$ ,  $r = 0.81$ ). The total number of mononuclear cells had significant positive correlation with bone marrow derived CD34+ cells ( $p < 0.01$ ,  $r = 0.78$ ). No significant association was found between mononuclear cells and CD34+ cells count with age and sex of patients. We found that the number of mononuclear cells and CD34+ cells were higher if greater amount of volumes of bone marrow was aspirated hence improving the chances of recovery.

**KEYWORDS:** SCI, CD34+, MNCs, BMC, BM.

### INTRODUCTION

With technical advancement, huge advances have been made worldwide in the adult stem cell field. Several donor sites can be used for obtaining mononuclear stem cells of bone marrow. Bone marrow was the first source of mononuclear stem cells for experimental and later for clinical use. For experimental use, it is still probably the best and most accessible, as small amounts of bone blood can be easily aspirated in local analgesia. Site of aspiration is usually from the posterior iliac crests.

High velocity injuries have severely exposed the limitations of the conventional managements of severely injured patients and morbidity of the patients has increased greatly. Spinal injury associated with complete cord (neurological) involvement has been recorded for hundreds of years.<sup>[1]</sup> The hopelessness and helplessness experienced by both patients and treating doctors is responsible for the use of stem cells in the field of spinal cord injury management. The incidence of spinal cord injury is estimated at between 35 and 80 per million of population per year in most nations and as yet shows no sign of reduction.<sup>[2, 3, 4]</sup>

It has long been believed that intrinsic repair is quite restricted after spinal cord injury because neurogenesis rarely occurs in the central nervous system (CNS). As a result stem cell transplantation has become a promising therapeutic option for spinal cord injury (SCI) patients.

A stem cell has the capability of forming various tissues under specific signals received from the body and the surroundings. The aim of stem cell therapy is to repair a damaged tissue that has lost the property to heal itself. In order to accomplish this goal, stem cells have been transplanted into the damaged area, directing them to grow a new, healthy tissue. The use of autologous bone marrow cells (BMCs) for stem cell therapy in SCI patients has more advantages. First one can avoid all problems associated with the immunological rejection or graft-versus-host reactions<sup>[5]</sup> which are frequently caused in allogenic cell transplantation. Secondly autologous BMC therapy is considered safe by not being associated with carcinogenesis.<sup>[6]</sup>

Some studies show that the total no of mononuclear cells obtained for transplantation was  $4 \times 10^8$  cells and the CD34+ cells in them was  $90 \times 10^6$  cells.<sup>[7]</sup> Mononuclear

stem cells are contained in bone marrow (BM) aspirates in a concentration of approximately 10-100 MSC per  $1 \times 10^6$  BM cells.<sup>[8,9,10,11,12]</sup> In this study we have found that in  $10^8$  bone marrow cells, around 1 to  $3 \times 10^7$  CD34<sup>+</sup> cells are present.

The present study was conducted to evaluate the concentration of MNCs and its CD 34 positive cell fraction in the infusion sample of the autologous bone marrow concentrate used in the SCI patients.

## MATERIAL AND METHODS

A prospective study was conducted in the Department of Transfusion Medicine in collaboration with Department of Orthopaedic Surgery, King George's Medical University Lucknow. Patients of acute spinal cord injury were taken from the Orthopedics Department KGMU, Lucknow. Patients with loss of motor and sensory functions due to injury between T6 and L3 skeletal levels were selected. Time elapsed since injury was noted. Complete history, neurological examination of the patient with all the necessary investigations was done.

**Procedure:** 70-180 ml bone marrow was aspirated from the posterior iliac crests under general anaesthesia (GA). Bone marrow aspirate- was collected in CPDA blood bags and processed by sedimentation and centrifugation in a closed sterile system following good laboratory practices in Component Laboratory of Transfusion Medicine Department, KGMU. Mononuclear stem cells were isolated and quantified for automated counts as well as CD34 counts.

After processing infusion of volume approx 8-10 ml was re-infused in the patient at the time of surgery at the site of injury into spinal cord.

The patient was monitored for recovery of motor and sensory loss till 6 weeks and then called for regular follow up after every one month.

Monitoring of recovery was done by ASIA method.

## Investigation and Techniques used

**Cell counts:** It was done by automated cell count and confirmed by Neubauer's chamber.

**CD34+ Count:** It was done by immunoflowcytometer for bone marrow mononuclear cells.

## RESULTS

As shown in Table 1 that 44 cases of spinal cord injury were included in our study. Out of them 36 (81.8%) were males and 8(18.2%) were females. Age ranged from 14yrs to 51 yrs. In which 4(9%) patients had age below 20 yrs and 6(14%) patients had age above 40 yrs. The most prevalent age group at injury was both 20-30 yrs and 31-40yrs group with equal distribution (39% each). The mean age at the time of injury was  $32.70 \pm 9.80$  yrs. The most common cause of injury was fall from height (n=25; 57 %). The level of Motor Loss is shown in Table 2 for 44 patients. Majority of cases showed complete paraplegia below L1 i.e. 18 (41%) followed by L2-. 11 (25%), T 12- 8 (18%). Other levels have percentage less than 10. The sensory status of the patients was also assessed in all the cases and it is found that the anaesthesia levels were related almost as per motor level. Majority of cases showed (Table 3) anaesthesia below L1 i.e. in 24 (54.54%) cases, followed by L2 in 12 (24.27%), L3 in 1 (2.27%), T10 in 3 (6.81%) and below T12 in 4 (9.09%) cases.

**Table 1: Age and Sex distribution of the SCI patients**

Age Group (in years) ↓	Sex →	Male	Female	Total	Percentage
		<b>36</b>	<b>8</b>	<b>44</b>	<b>100 %</b>
< 20		3	1	4	9 %
20-30		16	1	17	39 %
31-40		14	3	17	39 %
>40		3	3	6	14 %

**Table 2: Relation between mode of injury and motor loss**

Mode of injury ↓	Levels of motor loss							Total cases in different types of mode of injury	%
	*T6	*T8	*T10	*T12	*L1	*L2	*L3		
Direct fall from height	0	0	2	7	8	7	1	<b>25</b>	<b>57</b>
Indirect fall from height	0	0	0	0	3	0	0	<b>3</b>	<b>7</b>
Fall of weight on body	0	0	1	0	4	3	0	<b>8</b>	<b>18</b>
Motor vehicle accidents	1	1	0	1	3	1	1	<b>8</b>	<b>18</b>
Total cases in different levels	<b>1</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>18</b>	<b>11</b>	<b>2</b>	<b>Total cases=44</b>	
%	<b>2</b>	<b>2</b>	<b>7</b>	<b>18</b>	<b>41</b>	<b>25</b>	<b>5</b>		

\* Complete paraplegia below \_\_\_

**Table 3: Type and Level of Sensory loss**

Diagnosis	No.(n=44)	%
Anaesthesia below L1	24	54.54
Anaesthesia below L2	12	27.27
Anaesthesia below T10	3	6.81
Anaesthesia below T12	4	9.09
Anaesthesia below L3	1	2.27

**Association of sex and age with count of CD34+ cells:** No significance difference was found with the count of CD34+ cells with the sex of the patients (Table 4). Maximum mean of CD 34+ count was found in the age group of above 40 years (Table 5).

**Table 4: Means of CD 34 count in different Sexes**

Sex type	Means of % CD 34 count ± Standard deviation
Male	0.3900 ± 0.2163
Female	0.3531 ± 0.3258
P-value = 0.7622 (insignificant)	

**Table 5: Means of CD 34 in different Age groups**

Age groups (in years)	Means of % CD 34 count ± Standard deviation
< 20	0.1850 ± 0.1436
20- 30	0.3029 ± 0.2443
31- 40	0.4282 ± 0.3990
> 40	0.4433 ± 0.1945

**Association between aspirated volumes of bone marrow with bone marrow derived mononuclear cells, (Table-6):** The mean of the total number of mononuclear cells was  $2.18 \pm 1.24 \times 10^6$  (median  $2.08 \times 10^6$ , range  $0.09-4.88 \times 10^6$ ) in the aspirated volume of 70-120 ml bone marrow aspirated. The mean of the

total number of mononuclear cells was  $6.8 \pm 1.48 \times 10^6$  (median  $7.08 \times 10^6$ , range  $3.90-8.87 \times 10^6$ ) in the aspirated volume of 130-180 ml bone marrow aspirated. There was a significant positive correlation of the total volume of bone marrow aspirated with bone marrow derived mononuclear cells ( $p < 0.01$ ,  $r = 0.92$ ).

**Table 6: Comparison of mononuclear cells on the basis of aspirated bone marrow volume (ml)**

Characteristics	Total number of Mononuclear cells		
	Mean ± SD ( $\times 10^6$ )	Median ( $\times 10^6$ )	Mean range ( $\times 10^6$ )
Total volume aspirated (ml) ↓			
70-120	$2.18 \pm 1.24$	2.80	0.09 - 4.88
130-180	$6.8 \pm 1.48$	7.08	3.90 - 8.87
(p<0.01, r=0.92)			

**Association between aspirated volumes of bone marrow with bone marrow derived CD34+ cells (Table 7)** The mean of the total number CD34+ cells was  $2.41 \pm 1.198 \times 10^6$  (median  $1.98 \times 10^6$ , range  $1.09-4.94 \times 10^6$ ) in the aspirated volume of 70-120 ml bone marrow aspirated. The mean of the total number CD34+

cells was  $7.51 \pm 1.71 \times 10^6$  (median  $7.15 \times 10^6$ , range  $4.11-9.90 \times 10^6$ ) in the aspirated volume of 130-180 ml bone marrow aspirated. The volume of bone marrow aspirated had a significant positive correlation with the number of bone marrow derived CD34+ cells ( $p < 0.01$ ,  $r = 0.81$ ).

So the data shown in table 6 and 7 clearly indicates that volume of aspiration of range 130-180 ml has much more significant count of MNCs and CD 34 positive cells as compared to range 70-120 ml.

**Table 7: Comparison of CD34+ cells on the basis of aspirated bone marrow volume (ml)**

Characteristics	Total number of CD34+ cells		
	Mean ± SD ( $\times 10^6$ )	Median ( $\times 10^6$ )	Mean range ( $\times 10^6$ )
Total volume aspirated (ml) ↓			
70-120	$2.41 \pm 1.198$	1.98	1.09 - 4.94
130-180	$7.51 \pm 1.71$	7.15	4.11 - 9.90
(p<0.01, r=0.81)			

**Association between total numbers of mononuclear cells with bone marrow derived CD34+ cells; (Table 8):** The mean of the total number of CD34+ cells was  $2.07 \pm 0.82 \times 10^6$  (median  $1.93 \times 10^6$ , range 1.09-3.90) when the total number of mononuclear cells were  $0.79-4.88 \times 10^6$ . The mean of the total number of CD34+ cells was  $6.45 \pm 1.84 \times 10^6$  (median  $6.25 \times 10^6$ , range 4.11-9.90) when the total number of mononuclear cells were  $2.09-8.87 \times 10^6$ . The total number of mononuclear cells had a significant positive correlation with bone marrow derived CD34+ cells ( $p < 0.01$ , range=0.78).

Table 9 has summarized information's showing means of various related variable such as the mean of the total volume aspirated from spinal cord injury patients was

$126.70 \pm 31.93$  ml (mean range =117-136.41 ml) and the mean of the total volume of mononuclear cell suspension infusion was  $10.08 \pm 2.41$  ml (mean range = 9.35-10.81 ml). The mean of the lymphocytes, monocytes and mononuclear cells count before RBC depletion were  $2.63 \pm 1.18 \times 10^3/\mu\text{l}$  (mean range =  $2.27-2.99 \times 10^3/\mu\text{l}$ ),  $0.97 \pm 0.57 \times 10^3/\mu\text{l}$  (mean range =  $0.79-1.14 \times 10^3/\mu\text{l}$ ), and  $3.61 \pm 1.58 \times 10^3/\mu\text{l}$  (mean range =  $3.13-4.09 \times 10^3/\mu\text{l}$ ) respectively. We extracted CD34+ stem cells count from bone marrow aspirate and the mean percentage of CD34+ cells concentration was  $0.36 \pm 0.37$  % (0.25-0.48 %) and the mean of the total number of CD34+ cells infusion in the patients was  $3.21 \pm 2.20 \times 10^7$  with mean range (2.54-3.88  $\times 10^7$ ).

**Table 8: Comparison of total number of CD34 + cells on the basis of the number of mononuclear cells**

Mononuclear cells Range ( $\times 10^6$ )	Total number of CD34+ cells		
	Mean $\pm$ SD ( $\times 10^6$ )	Median ( $\times 10^6$ )	Mean range ( $\times 10^6$ )
0.79-4.88	$2.07 \pm 0.82$	1.93	1.09 - 3.90
2.09-8.87	$6.45 \pm 1.84$	6.25	4.11 - 9.90
$(p < 0.01, r = 0.78)$			

**Table 9: Distribution of Parameters**

Parameters	Mean $\pm$ SD (95% Confidence interval)	Mean range
Total volume aspirated	$126.70 \pm 31.93$ ml	(117.00 - 136.41)
Lymphocytes count	$2.63 \pm 1.18 \times 10^3/\mu\text{l}$	$(2.27 - 2.99) \times 10^3/\mu\text{l}$
Monocytes count	$0.97 \pm 0.57 \times 10^3/\mu\text{l}$	$(0.79 - 1.14) \times 10^3/\mu\text{l}$
Mononuclear cells count	$3.61 \pm 1.58 \times 10^3/\mu\text{l}$	$(3.13 - 4.09) \times 10^3/\mu\text{l}$
Volume of infusions	$10.087 \pm 2.41$ ml	(9.35 - 10.81) ml
CD34+ (%)	$0.36 \pm 0.37$	(0.25 - 0.48)
Total no. of CD34+ cells infused	$3.21 \pm 2.20 \times 10^7$	$(2.54 - 3.88) \times 10^7$

## DISCUSSION

Spinal cord injury is a major neurological problem affecting people at large. Stem cell transplantation in spinal cord injury patients has shown a ray of light. Different sources of stem cells are being exploited for spinal cord injury as well as other neurological disorders.<sup>[13]</sup>

Most of the studies in medical literature are from advanced countries where the problem and presentations are different with respect to mode of injury, sex, incidence etc. The age distribution of patient is comparable with studies from the other parts of India and world. Most commonly affected age group being 20-29.<sup>[14]</sup> In our study the most prevalent age group was 20-40 years. In both 20-30 yrs and 31-40yrs group had equal prevalence of SCI of 39%.

Sex distribution has shown a male female ratio in this study. 81.8% (n=36) of spinal cord injury patients were males and 18.2% (n=8) were females, which is comparable to other recent studies.<sup>[15]</sup> (13.5 Male : 1 Female),<sup>[16]</sup> (8.98 Male:1 Female),<sup>[17]</sup> (3.7 Male:1 Female),<sup>[18]</sup> (3.7Male:1 Female),<sup>[19]</sup> (2.5Male:1

Female),<sup>[20]</sup> (4Male:1 Female),<sup>[21]</sup> (4.3 Male: 1 Female),<sup>[14]</sup> (2.96 Male:1Female). These studies reflect a changing trend as they cover a period of 15-20 years.

A study found that the most common cause of injury was fall from height including roof, trees, electricity pole (44.5%) followed by motor vehicle accident (34.7%). Falls were more common in second and third decades. Road side accidents were also commoner in third and fourth decades.<sup>[14]</sup> In our study, 25(57%) spinal cord injuries occurred due to direct fall from height, 3(7%) due to indirect fall from height, 8(18%) due to fall of weight over body and 8(18%) due to motor vehicles accidents.

The anatomical level of injury in the spinal cord is divided into high (cervical) and low injuries (thoracic, lumbar and sacral). The neurological level of injury is defined as the most caudal segment of the spinal cord that has normal function.<sup>[22,23]</sup> The neurological assessment has an importance in making clinical diagnosis, for monitoring and also had prediction of functional outcomes. In 10 - 15 % of the patients with traumatic spinal cord injury there is a difference between

the anatomical and the neurological levels of injury. The reason is probably due to multi-level injuries, vascular pathologies and/or a spinal-cord oedema following injury.<sup>[24]</sup> A study found that out of 483, 164 patients were tetraplegics and 283 patients were paraplegics, while 36 patients had no neurological deficit. Dorsolumbar spine injury was commonest with first lumbar being the most common fractured vertebrae followed by twelfth dorsal vertebrae; cervical spine was next with most common site being fifth and sixth cervical vertebrae<sup>[14]</sup> In our study we found that out of 44 patients of paraplegia 18 (in 41% cases) patients has complete paraplegia below L1, 11 (in 25% cases) with complete paraplegia below L2, 8(in 18% cases) with complete paraplegia below T12 and rest of the cases were found below 10%. Radiologically 18 patients had fracture at T12 vertebrae, 15 patients had fracture at L1 vertebrae and 2 patients had dislocation at T11 over T12 vertebrae. 4, 1 and 4 patients had fracture at L2 vertebrae, L3 vertebrae and T12 vertebrae respectively. Further, we found that out of 44 cases, 24 patients had anaesthesia below L1, 12 below L2, 1 below L3, 3 below T10 and 4 below T12.

CD34 is an antigen expressed on early uncommitted and committed progenitor cells.<sup>[25]</sup> A study suggested that the infused CD34<sup>+</sup> PBPC (peripheral blood progenitor cell) dose could be used as a predictor of hematopoietic recovery after engraftment. Since then, a direct correlation between the numbers of collected or infused CD34<sup>+</sup> cells/kg of body weight and the recovery of hematologic has been identified by many investigators.<sup>[26]</sup> The CD34<sup>+</sup> cell dose has a more profound effect on recovery of platelets than granulocytes.<sup>[25]</sup> In this study CD34 is used as a surrogate maker for stem cell infusion. In 10<sup>8</sup> bone marrow cells, around 1 to 3 × 10<sup>6</sup> CD34 cells are present. In the present study approximately 70-180 ml bone marrow were harvested from iliac crest and mononuclear cells were concentrated to the final volume of approximately (8-10 ml). While in the other study they concentrated final volume of mononuclear cells to 1.8 ml.<sup>[27]</sup> that was infused into the surrounding area of the injury site. A study showed the mononuclear cells were resuspended in saline and autologous plasma for a total volume of 80 ml.<sup>[7]</sup>

A study reported that the total volume of cells aspirated from the ileum was 728±72 ml (range 600 to 800) per patient, and the total volume of injected BM-MNCs was 45±7 ml (range 30 to 50) per patient. Total number of injected BM-MNCs was 3.5±0.8×10<sup>9</sup> (range 2.0 to 4.7×10<sup>9</sup>), and that of CD34<sup>+</sup> cells was 6.8±2.6×10<sup>7</sup> (range 2.4 to 9.7×10<sup>7</sup>).<sup>[28]</sup> In our study the mean of the total volume aspirated from spinal cord injury patient was 126.70±31.93 ml (117.00-136.41) and the mean of volume of mononuclear cell suspension infusion was 10.08± 2.41 ml (9.35-10.81).The mean of the mononuclear cells before RBC depletion was 3.61±1.58 × 10<sup>3</sup>/μl (3.13-4.09× 10<sup>3</sup>/μl).The mean of the

mononuclear cells count before RBC depletion, total volume aspirated and volume of infusion were 3.79± 1.59 cells/μl, 125.97± 31.42ml, 10.18 ± 2.45 ml respectively in a male group of spinal cord injured patients. The mean of the mononuclear cells count before RBC depletion, total volume aspirated and volume of infusion were 2.76± 1.27 × 10<sup>3</sup>/μl, 130± 36.25 ml, 9.36 ± 2.33 ml respectively in a female group of spinal cord injured patients.

There is a need to define a minimum safety threshold for CD34<sup>+</sup> cell dose for haematopoietic cell transplantation. This minimum dose would define a cell number in the graft, below which an unacceptable proportion of patients would be expected to have delayed hematopoietic recovery or failure to engraft. Some studies show that the average total CD34<sup>+</sup> obtained for transplantation was 90×10<sup>6</sup> cell.<sup>[27]</sup> In our study the mean percentage of the CD34<sup>+</sup> cells concentration was 0.36±0.37 % (0.25-0.48) while mean of the total number of CD34<sup>+</sup> cell infused patients were 3.21± 2.20 × 10<sup>7</sup> (2.54-3.88×10<sup>7</sup>). We also found that the mean percentage of CD34<sup>+</sup> cells concentration and the total CD34<sup>+</sup> cells infused in male's spinal cord injured patients were 0.36± 0.40 %, 3.22± 1.97×10<sup>7</sup> cells respectively. While the mean percentage of CD34<sup>+</sup> cells concentration and the total CD34<sup>+</sup> cells infused in female's spinal cord injured patients were 0.39± 0.22%, 3.18± 3.23×10<sup>7</sup> cells respectively.

## CONCLUSION

As a result of this study we were able to standardize our techniques for collection, processing and infusion of bone marrow mononuclear cells. We found that the number of mononuclear cells and CD34<sup>+</sup> cells were higher if greater amount of volumes of bone marrow was aspirated hence improving the chances of recovery. Infusion volume of approximately 9 ml was appropriate for transfusing these cells at the site of injury. Hence concentration and volumes of bone marrow plays a significant role in the further stem cell treatment of spinal cord injury. Commonest population in Indian prone to SCI are males in the age group of 20-40 years. Usually that fall is direct from a height and majority have shown sensory loss below L1.

## ACKNOWLEDGEMENT

We will like to acknowledge the sincere efforts of our research scholars Ashok Agrahari, S. Nishat Fatima Rizvi, Sheeba Afreen and Saloni Raj whose contribution helped us in our work.

## REFERENCES

1. Blau.O, Hofmann W.K, Baldus C.D, Thiel G, Serbent V, Schümann E, Thiel E. & Blau I.W.Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia...*Experimental Hematology*. 2007; 35: 221-229.

2. Schwab ME. Regenerative Nerve Fiber Growth in the Adult Central Nervous System. *News Physiol Sci.* 1998; 13: 294-8.
3. Treherne JM, Woodward SK, Varga ZM, Ritchie JM, Nicholls JG. Restoration of conduction and growth of axons through injured spinal cord of neonatal opossum in culture. *Proc Natl Acad Sci U S A.* 1992; 89: 431-4.
4. Case LC, Tessier-Lavigne M. Regeneration of the adult central nervous system. *Curr Biol.* 2005; 15:749-53.
5. Luck R, Klempnauer J, Steiniger B. Simultaneous occurrence of graft- versus-host and host-versus-graft reactions after allogenic MHC class II disparate small bowel transplantation in immunocompetent rats. *Transplant Proc.* 1991; 23: 677-678.
6. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. *Nature.* 2004; 432: 324-331.
7. L. F. Geffner, P. Santacruz, M. Izurieta, L. Flor, B. Maldonado, A.H Auad, X. Montenegro, R.Gonzalez, and F. Silva. Administration of Autologous Bone Marrow Stem Cells into Spinal Cord Injury Patients via Multiple Routes Is Safe and Improves Their Quality of Life: Comprehensive Case Studies. *Cell Transplantation.* 2008; 17:1277-1293
8. Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. *J Cell Biochem.* 1994; 56: 283-294.
9. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first trimester fetal blood, liver, and bone marrow. *Blood.* 2001; 98:2396-2402.
10. Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. *J Bone Joint Surg Am.* 2005; 87: 1430-1437.
11. Prockop DJ, Azizi SA, Colter D, Digirolamo C, Kopen G, Phinney DG. Potential use of stem cells from bone marrow to repair the extracellular matrix and the central nervous system. *Biochem Soc Trans.* 2000; 28: 341-345.
12. Wexler SA, Donaldson C, Denning-Kendall P, Rice C, Bradley B, Hows JM. Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. *Br J Haematol.* 2003; 121: 368-374.
13. Syed Ameer Basha Paspala, Avvari Bhaskara Balaji, Parveen Nyamath, Khawaja Shakeel Ahmed, Aleem Ahmed Khan, Mohammed Nane Khaja, M. Lakshmi Narsu, Y. Prameela Devi, T.V.R.K. Murthy & C.M. Habibullah. Neural stem cells & supporting cells - The new therapeutic tools for the treatment of spinal cord injury. *Indian J Med Res.* 2009; 130:379-39.
14. Roop Singh, Sansar Chand Sharma, Rajeev Mittal, Ashwini Sharma. Traumatic Spinal Cord Injuries in Haryana: An Epidemiology Study. *Indian Journal of Community Medicine.* 2003; 28: 4.
15. Chacko V, Joseph B, Mohanty SP, Jacob T. Management of spinal cord injury in a general hospital in rural India. *Paraplegia.* 1986; 24: 330-5.
16. Shanmuga Sundram TK. Final report of Madras Paraplegia Project. Madras.
17. Dave PK, Jayaswal A, Kotwal PP. (1994) Spinal cord injuries - A clinico-epidemiological study. *Ind J Orthop.* 1987; 28: 39- 45.
18. David C. Medical complications during acute rehabilitation following spinal cord injury - current experience of model systems. *Arch Phys Med Rehabil.* 1999; 80: 1397-1401.
19. Karacan I, Koyuncu H, Pekel O, Sumbuloglu G, Kirnap M, Dursum H et al. Traumatic spinal cord injuries in Turkey: a nationwide epidemiological study. *Spinal Cord.* 2000; 38(11): 697-701.
20. Lan C, Lai JS, Chang KH, Kan YC, Lein In. Traumatic spinal cord injuries in the rural region of Taiwan: an epidemiological study in Hualien Country 1986-1990. *Paraplegia.* 1993; 31(6): 398-403.
21. Shingu H, Ikata T, Katoh S, Akatsu T. Spinal cord injuries in Japan: A nationwide epidemiological survey in 1990. *Paraplegia.* 1994; 32(1): 3-8.
22. Ditunno JF jr, Young W, Donovan WH et al. The international standards booklet for neurological and functional classification of spinal cord injury. *Paraplegia.* 1992; 32: 70 - 80.
23. Maynard FM jr, Bracken MB, Creasey G et al. International standards for neurological and functional classification of spinal cord injury. *Spinal Cord.* 1997; 35: 266 - 74.
24. Rowland JW, Hawryluk GW, Kwon B et al. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. *Neurosurg Focus.* 2008; 25: E2-E5.
25. Elizabeth J. Shpall, Richard Champlin, John A. Glaspy. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. *Biology of Blood and Marrow Transplantation.* 1998; 4: 84-92.
26. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern AC, Lansdorp PM, Bonadonna G, Gianni AM. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. *Blood.* 1991; 77: 400.
27. Seung Hwan, Yu Shik Shim, Yong Hoon Park, Jong Kwon Chung, Jung Hyun Nam, Myung Ok Kim, Hyung Chun Park, So Ra Park, Byoung-Hyun Min, Eun Young Kim, Byung Hyune Choi, Hyeonseon Park, Yoon Ha. Complete Spinal Cord Injury Treatment Using Autologous Bone Marrow Cell Transplantation and Bone Marrow Stimulation with Granulocyte Macrophage Colony Stimulating

Factor: Phase I/II Clinical Trial. *Stem Cells*. 2007; 25: 2066–2073.

28. Koji Miyamoto, Kazuhiro Nishigami, Noritoshi Nagaya, Koichi Akutsu, Masaaki Chiku, Masataka Kamei, Toshihiro Soma, Shigeki Miyata, Masahiro Higashi, Ryoichi Tanaka, Takeshi Nakatani, Hiroshi Nonogi, Satoshi Takeshita. Unblinded Pilot Study of Autologous Transplantation of Bone Marrow Mononuclear Cells in Patients with Thromboangiitis Obliterans. *Circulation*. 2006; 114: 2679-2684.